Keyphrases
Simian Immunodeficiency Virus
81%
Rhesus Macaque
35%
Human Immunodeficiency Virus Type 1 (HIV-1)
34%
Lymphatic Tissue
27%
Virus Infection
26%
Immune Activation
25%
Virus
21%
Vaccine Correlates
20%
Correlates of Protection
20%
Virus Entry
17%
CD4+ T Cells
17%
SIV Infection
16%
Epithelium
15%
Infected Cells
15%
HIV Infection
14%
Cell-Associated
14%
Gp41
14%
Cell Response
14%
Cervical Epithelium
13%
In Situ
13%
HIV-1 Infection
13%
Virus Vaccine
13%
Vaginal Exposure
13%
Immune Response
11%
Inoculation
11%
AIDS/HIV
11%
Early Infection
11%
Founder Population
10%
Immune Complex
10%
Innate Response
10%
Macrophages
9%
Female Reproductive Tract
9%
Persistent Infection
9%
High Dose
9%
Trimeric
8%
Vaccination
8%
Antiretroviral Therapy
8%
Outcome Prediction
8%
Virus Transmission
8%
Virus Replication
8%
Antibody Production
8%
Vaginal Transmission
8%
CD4 T Cells
8%
HIV Transmission
7%
Productive Infection
7%
Acute Stage
7%
Infection Outcome
6%
In Situ Tetramer Staining
6%
Virus-specific CD8+ T Cells
6%
Antigen-specific Cells
6%
Immunology and Microbiology
Simian Immunodeficiency Virus
100%
Human Immunodeficiency Virus 1
47%
Rhesus Monkey
42%
Virus
34%
Human Immunodeficiency Virus
34%
T-Helper Cell
32%
Viral Disease
28%
Viral Entry
25%
Human Immunodeficiency Virus Infection
17%
Target Cell
15%
Gp41
14%
Cytotoxic T-Cell
13%
Simian Immunodeficiency Virus Vaccine
13%
Immunosuppressive Drug
13%
Macrophage
11%
Immune Complex
10%
Viral Replication
10%
Lymphatic Follicle
10%
Immune Response
9%
Drug Megadose
9%
Virus Transmission
8%
Rebound
8%
Antibody Generation
7%
B Cell
7%
T Cell
7%
Immunodeficiency
6%
Neutralizing Antibody
6%
Alveolar Macrophage
6%
Follicular Dendritic Cells
6%
Antigen Specificity
6%
Gene Transfer
6%
Natural Killer Cell
6%
Fc Receptor
6%
Osteopontin
6%
Cercocebus atys
6%
Viral Load
6%
Regulatory T Cell
6%
Glucocorticoid
6%
Immunoglobulin Producing Cell
6%
Programmed Cell Death
6%
Viral Envelope
6%
Glycerol
6%
Innate Immune Cell
6%
Chemokine
6%
Haplorhini
5%
Macaca
5%
In Situ Hybridization
5%
Lymphoid Tissue
5%
